Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Ringing the Changes on Variations for Veterinary Medicines

This article was originally published in SRA

  • News

Executive Summary

Revisions to EU law on amending marketing authorisations will boost the competitiveness of the veterinary pharmaceutical industry, says Sylvie Meillerais.

You may also be interested in...



EMEA Round-Up: Bayer Strikes Egypt Deals, Orkla Acquires NutraQ, Uriach Grabs Sidroga

Round-up of the latest news across EMEA, including two deals for Bayer in Egypt and Saudi Arabia; Orkla's acquisition of NutraQ; and Uriach's deal for Sidroga.

TheOTCLab Scores Dutch Distribution Rights To Just For Men, Vagisil and Breathe Right

Dutch firm TheOTCLab expands its home market presence with distribution rights to three international consumer health brands: Combe's feminine health brand Vagisil and male hair care range Just For Men and Foundation Consumer Brands’ Breathe Right Nasal Strips.

Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand

Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By